# An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

> **NCT00153010** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 430 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** NS 2330 (Tesofensine)

## Key facts

- **NCT ID:** NCT00153010
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2005-03
- **Final completion:** —
- **Target enrollment:** 430 (ACTUAL)
- **Last updated:** 2013-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00153010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00153010, "An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00153010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*